Literature DB >> 17767978

Effect of aminoisobutyric acid (Aib) substitutions on the antimicrobial and cytolytic activities of the frog skin peptide, temporin-1DRa.

J Michael Conlon1, Rokaya Al-Kharrge, Eman Ahmed, Haider Raza, Sehamuddin Galadari, Eric Condamine.   

Abstract

Temporin-1DRa (HFLGTLVNLAKKIL.NH(2)), first isolated from the skin of the California red-legged frog Rana draytonii, shows broad-spectrum antimicrobial activity but its therapeutic potential is limited by its toxicity against mammalian cells. The cytolytic properties of cationic alpha-helical peptides are determined by a complex interaction between cationicity, hydrophobicity, conformation, and amphipathicity. This study has investigated the cytolytic properties of conformationally constrained analogs of temporin-1DRa containing alpha-aminoisobutyric acid (Aib) substitutions. Cytolytic activity was determined against the bacteria Escherichia coli and Staphylococcus aureus, the opportunistic yeast pathogen, Candida albicans, human erythrocytes, HepG2 hepatoma-derived cells, and L929 fibroblasts. Aib substitutions at Gly(4), Asn(8), and Ala(10) increased both % helicity, determined in methanol solution, and hydrophobicity resulting in increases in both antimicrobial potencies and toxicities against the mammalian cells. Substitution at Leu(6) resulted in an appreciable decrease in cytolytic activity against all cells whereas the substitutions at His(1), Phe(2), Leu(3), Thr(5), and Val(7) had only minor effects on activity. Substitutions at Leu(9), Ile(13), Leu(14) produced analogs with decreased helicity and hydrophobicity that retained activity against microorganisms but showed appreciably lower cytolytic activities against mammalian cells. In particular, the fourfold increase in therapeutic index [ratio of LC(50) against erythrocytes to minimum inhibitory concentration (MIC) against microorganisms] of [Aib(13)]temporin-1DRa identifies it as a compound with potential for development as a therapeutically valuable anti-infective agent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17767978     DOI: 10.1016/j.peptides.2007.07.023

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

Review 1.  Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action.

Authors:  Maria Luisa Mangoni; Yechiel Shai
Journal:  Cell Mol Life Sci       Date:  2011-05-15       Impact factor: 9.261

2.  In vitro and intracellular activities of frog skin temporins against Legionella pneumophila and its eukaryotic hosts.

Authors:  Alexandre Crépin; Jean-François Jégou; Sonia André; Florine Ecale; Anastasia Croitoru; Anne Cantereau; Jean-Marc Berjeaud; Ali Ladram; Julien Verdon
Journal:  Sci Rep       Date:  2020-03-04       Impact factor: 4.379

3.  D- and Unnatural Amino Acid Substituted Antimicrobial Peptides With Improved Proteolytic Resistance and Their Proteolytic Degradation Characteristics.

Authors:  Jianguang Lu; Hongjiang Xu; Jianghua Xia; Jie Ma; Jun Xu; Yanan Li; Jun Feng
Journal:  Front Microbiol       Date:  2020-11-12       Impact factor: 5.640

4.  Selection of antimicrobial frog peptides and temporin-1DRa analogues for treatment of bacterial infections based on their cytotoxicity and differential activity against pathogens.

Authors:  Rogier A Gaiser; Jaione Ayerra Mangado; Milena Mechkarska; Wendy E Kaman; Peter van Baarlen; J Michael Conlon; Jerry M Wells
Journal:  Chem Biol Drug Des       Date:  2020-09-19       Impact factor: 2.817

5.  The influence of solvent on conformational properties of peptides with Aib residue-a DFT study.

Authors:  Roksana Wałęsa; Małgorzata A Broda
Journal:  J Mol Model       Date:  2017-11-21       Impact factor: 1.810

6.  Co-culture of Bacillus amyloliquefaciens ACCC11060 and Trichoderma asperellum GDFS1009 enhanced pathogen-inhibition and amino acid yield.

Authors:  Qiong Wu; Mi Ni; Kai Dou; Jun Tang; Jianhong Ren; Chuanjin Yu; Jie Chen
Journal:  Microb Cell Fact       Date:  2018-10-03       Impact factor: 5.328

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.